ImmunityBio, Inc. - Common Stock (IBRX)

The company said it plans to submit a biologics license application by the fourth quarter of 2026.

Data from Stocktwits showed that retail sentiment on SPY and QQQ diverged.

The filing comes ahead of ImmunityBio’s participation in the ASCO Genitourinary Cancers Symposium.

Traders debated whether Trump could reference cancer priorities or FDA reform, with some betting a mention could spark another leg higher for IBRX.

ImmunityBio outlined a three-year plan to position Anktiva as a backbone immunotherapy, advancing more than 30 trials across 10 tumor types.

On Feb. 23, 2026, investors weighed ANKTIVA’s explosive revenue ramp against ImmunityBio’s deep losses and ambitious global expansion.

ImmunityBio's stock has roughly quintupled so far in 2026 as the company continues to deliver good news for investors.

Net product revenue in the fourth quarter surged 431% to $38.3 million, above estimates of $37.8 million, according to Fiscal.ai data

Data from Stocktwits indicated retail sentiment on SPY and QQQ has been ‘bearish’.

The chairman pointed to upcoming updates on IL-15’s long-studied role in cancer immunotherapy.

ImmunityBio announced that it has partnered with Biopharma and Cigalah and hopes to launch Anktiva across the broader Middle East and North Africa (MENA) region over time.

Data from Stocktwits indicated retail sentiment on QQQ turned bearish amid elevated message volume.

Traders are closely watching positioning, as short interest hit a record 13.7% of the free float amid a jump in retail activity on Stocktwits this week.

As of February 19, 2026, ImmunityBio, Inc. (NASDAQ: IBRX) stands at a pivotal crossroads between clinical ambition and commercial reality. Once a "story stock" fueled by the vision of its billionaire founder, Dr. Patrick Soon-Shiong, the company has rapidly evolved into a commercial-stage powerhouse in the immunotherapy landscape. ImmunityBio is currently in focus due to [...]

The company also announced the establishment of an Irish subsidiary in Dublin to support its distribution and commercialization strategy across Europe.

Data from Stocktwits indicated retail sentiment towards SPY and QQQ cooled to neutral.

The standoff ended when the EU granted conditional approval, sending shares up 42% on Wednesday.

On Feb. 18, 2026, investors weighed ImmunityBio’s EU bladder cancer win against its long slide since IPO and fresh legal scrutiny.

The biopharma outfit's flagship cancer-fighting drug continues to rack up approvals.

The European Commission granted conditional marketing authorization to ImmunityBio’s Anktiva, implying that it wants more data from the company.